The Patent Finder

Terms ending in 2037

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,084,882Multispecific Antibodies Against CD40 and CD137
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,440,966Multispecific Antibodies Against CD40 and CD137
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,331,123Agent, Uses and Methods for Treatment
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
US 12,077,596Multispecific Antibodies Against CD40 and CD137
In force
 · High confidence
BioNTech SEIn forceHigh confidence
US 11,939,388Multispecific Antibodies Against CD40 and CD137
In force
 · High confidence
BioNTech SEIn forceHigh confidence
US 11,359,015Humanized or Chimeric CD3 Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Genmab A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited